BIRC3
BIRC3 (Baculoviral IAP repeat-containing protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 4 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signalling and immunity, mitogenic kinase signalling and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signalling and regulates both canonical and non-canonical NF-kappa-B signalling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signalling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an important regulator of innate immune signalling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. Location: Cytoplasm; Nucleus (UniProt). Locus 11q22.2 (HGNC).
- Non-Hodgkin lymphoma: Open Targets association 0.62 with non-Hodgkin lymphoma (MONDO_0018908)
- Leukaemia: Open Targets association 0.59 with leukaemia (MONDO_0005059)
- Skin cancer: Open Targets association 0.55 with skin cancer (MONDO_0002898)
- Mantle cell lymphoma: CIViC evidence names this disease
- Chronic lymphocytic leukaemia: CIViC evidence names this disease; IntOGen driver in 1 cohort (CLLSLL)
- Non-small-cell lung cancer: IntOGen driver in 1 cohort (LUSC)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"BIRC3" OR ABSTRACT:"BIRC3" OR TITLE:"baculoviral IAP repeat containing 3" OR ABSTRACT:"baculoviral IAP repeat containing 3" OR TITLE:"Baculoviral IAP repeat-containing protein 3" OR ABSTRACT:"Baculoviral IAP repeat-containing protein 3" OR TITLE:"cIAP2" OR ABSTRACT:"cIAP2" OR TITLE:"hiap-1" OR ABSTRACT:"hiap-1" OR TITLE:"RNF49" OR ABSTRACT:"RNF49") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BIRC3, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/birc3.json. Licence CC BY-NC 4.0.